Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
The landscape of new therapies in multiple myeloma trials is rapidly evolving, with stringent global regulations around blinded independent central review (BICR) for efficacy endpoints.
This webinar will review the challenges of conducting BICR and highlight how clinical trial sponsors can optimize endpoint assessments to meet their development goals. The panel includes Perceptive scientists with expertise in myeloma clinical trials and a globally-renowned myeloma physician with a blended background as a clinician AND an independent reader.
– Imaging and its relevance in the context of response evaluation – Relevance of PET and metabolic response for evaluation under IMWG criteria – Incorporating lesions on physical examination – Evaluating local and central lab datasets for efficacy with emphasis on the confirmation of progression – Suppression of light chains with newer therapies and methods to interpret them for response
"*" indicates required fields
Δ
